Flu shots work better in some years than others primarily because influenza viruses mutate rapidly, and scientists must predict which strains will circulate six to eight months before flu season actually begins. When those predictions miss the mark, the vaccine offers less protection. It is a fundamental timing and biology problem that no amount of manufacturing precision can fully solve. Consider the current 2025–2026 season: dominated by the notoriously unpredictable H3N2 strain, overall vaccine effectiveness in California has clocked in at just 33 percent, and for adults 65 and older, a mere 22 percent. Compare that to seasons where effectiveness has reached 56 percent, and you can see just how dramatically the numbers swing.
For people caring for someone with dementia or managing their own brain health, this variability matters more than it might for the general population. Older adults and those with compromised immune systems already mount weaker responses to the flu vaccine, and a bad flu season can accelerate cognitive decline, trigger delirium, or lead to hospitalizations that are difficult to recover from. Understanding why some years bring better protection than others is not just an academic question. It is a practical one that shapes decisions about when to get vaccinated, what type of vaccine to request, and how much to rely on other protective measures. This article breaks down the science behind flu vaccine variability, examines what makes certain strains so difficult to match, looks at this season’s specific numbers, and explores what new vaccine technologies might mean for more consistent protection in the years ahead.
Table of Contents
- What Makes Flu Shots More Effective in Certain Years Than Others?
- Why H3N2 Strains Make Flu Seasons Worse for Vaccine Protection
- How Age and Immune Health Change the Flu Shot’s Effectiveness
- When to Get the Flu Shot for the Best Protection
- Does Getting the Flu Shot Every Year Reduce Its Effectiveness?
- How Egg-Based Manufacturing Affects Vaccine Quality
- Could mRNA Technology Make Flu Shots More Consistent?
- Conclusion
- Frequently Asked Questions
What Makes Flu Shots More Effective in Certain Years Than Others?
The short answer is viral mismatch. every February, researchers at the World Health Organization and national health agencies examine surveillance data from around the globe and select the strains they believe will dominate the following fall and winter. vaccine manufacturers then spend months growing those specific strains, mostly in chicken eggs, and packaging them into the shots that arrive at pharmacies by September or October. The problem is that influenza viruses do not sit still during those intervening months. Through a process called antigenic drift, small mutations accumulate in the virus’s surface proteins, and by the time flu season arrives, the circulating strains may look different enough from the vaccine strains that the antibodies your body produces after vaccination no longer recognize them well. Since 2009, this guessing game has produced U.S.
vaccine effectiveness ranging from a low of 19 percent to a high of 56 percent, according to the CDC. To put that in perspective, imagine you are choosing a lock for your front door, but you have to pick the lock six months before you know what key a burglar will carry. Some years you get lucky and the lock holds. Other years the key has changed just enough to slip through. That is essentially what happens with flu vaccination, and it explains why public health officials still recommend the shot every year despite its inconsistency. Even partial protection reduces the severity of illness, lowers the risk of hospitalization, and can prevent death, particularly in vulnerable populations including older adults living with dementia.
Why H3N2 Strains Make Flu Seasons Worse for Vaccine Protection
Not all influenza strains are equally difficult to match. Influenza A(H3N2) is the consistent troublemaker. It mutates faster than other subtypes, and seasons dominated by H3N2 reliably produce lower vaccine effectiveness numbers. The 2025–2026 season is a textbook example. Heavily driven by H3N2 circulation, interim CDC data from September 2025 through February 2026 shows overall vaccine effectiveness against H3N2-associated outpatient illness at just 35 percent among children and adolescents, with effectiveness against H3N2 hospitalization at 38 percent. Meanwhile, the vaccine performed considerably better against influenza B strains during the same period, with effectiveness ranging from 45 to 71 percent among children and adolescents and reaching 63 percent among adults.
However, even in an H3N2-dominated season, skipping the flu shot is not the rational move, particularly for older adults or anyone in a caregiving role. The CDC estimates that during the October 2025 through February 2026 period alone, influenza caused at least 26 million illnesses, 340,000 hospitalizations, and 21,000 deaths in the United States. A vaccine that is 35 percent effective still prevents hundreds of thousands of those cases. The critical limitation to understand is that if you are over 65 or immunocompromised, your personal protection may be lower than the population-level numbers suggest. California-specific data from this season showed effectiveness of just 22 percent for adults 65 and older, compared to 39 percent for those aged six months to 17 years. That gap is not a reason to avoid vaccination but rather a reason to layer additional precautions on top of it.
How Age and Immune Health Change the Flu Shot’s Effectiveness
Age is one of the most significant factors determining how well the flu vaccine works for any individual, independent of whether the strain match is good or bad. Older adults naturally produce fewer and weaker antibodies in response to vaccination, a phenomenon called immunosenescence. For someone living with dementia, this challenge is compounded. Chronic neurological conditions, reduced physical activity, nutritional deficiencies, and the stress of cognitive decline all contribute to a less robust immune system. The result is that even in a year when the vaccine matches the circulating strains well, an 80-year-old with Alzheimer’s disease may get meaningfully less protection than a healthy 40-year-old receiving the same shot.
This is why the CDC and the Advisory Committee on Immunization Practices recommend high-dose or adjuvanted flu vaccines specifically for adults 65 and older. These formulations are designed to provoke a stronger immune response in aging immune systems. For caregivers, the calculus is slightly different but equally important. If you are providing daily care for someone with dementia, your vaccination protects not just you but the person you are caring for. Influenza transmission within households and care facilities is a major driver of serious illness in older adults who may not mount a sufficient immune response on their own, even with vaccination.
When to Get the Flu Shot for the Best Protection
Timing matters because flu vaccine protection wanes over the course of the season. The CDC has documented that antibody levels begin declining within a few months of vaccination, which creates a practical tradeoff. Get vaccinated too early, say in August, and your protection may have faded by the time flu activity peaks in January or February. Wait too long, and you risk catching the flu before the vaccine has had its full two weeks to take effect.
For most people, the CDC recommends vaccination by the end of October, though getting vaccinated later in the season still provides benefit. For older adults and dementia caregivers, the decision is worth discussing with a physician, because the optimal window may vary depending on local flu activity patterns and individual health factors. In institutional settings like memory care facilities, coordinating vaccination timing across residents and staff can be especially important, since a single introduction of the virus into a facility can spread rapidly among a population with weakened immune defenses. The tradeoff between early and late vaccination is real, but in practice, the best time to get the flu shot is whenever you can get it, rather than not getting it at all because the timing was not perfect.
Does Getting the Flu Shot Every Year Reduce Its Effectiveness?
This is one of the more uncomfortable questions in flu vaccine science, and the honest answer is that the evidence is mixed. Some studies have suggested that repeated annual vaccination may modestly blunt effectiveness in certain seasons, a phenomenon sometimes called the “antigenic distance hypothesis.” The theory is that your immune system may preferentially recall its response to previous vaccine strains rather than generating a robust new response to the current season’s strains. Research published in peer-reviewed journals indexed by the National Institutes of Health has explored this question without reaching a definitive consensus.
The important caveat is that even researchers who have documented this effect generally do not recommend skipping annual vaccination. The potential reduction in effectiveness from repeated vaccination appears to be small and inconsistent across seasons, while the cost of skipping a year, particularly for older adults or immunocompromised individuals, can be severe illness or death. For dementia caregivers and family members making decisions on behalf of someone who cannot weigh these nuances themselves, the mainstream medical recommendation remains clear: get vaccinated every year. The imperfect protection it provides is substantially better than none, and for someone whose cognitive and physical reserves are already diminished, avoiding a severe flu infection can be the difference between maintaining current function and experiencing a sharp, sometimes irreversible decline.
How Egg-Based Manufacturing Affects Vaccine Quality
Most flu vaccines in the United States are still produced using a decades-old process that involves growing the vaccine virus in fertilized chicken eggs. While this method is reliable and scalable, it introduces a subtle problem. As the virus replicates in eggs, it can undergo small mutations that help it grow better in that environment but make it slightly different from the wild-type virus circulating in humans.
These egg-adapted changes can reduce how well the resulting vaccine matches the actual flu strains people encounter. The CDC has acknowledged this as one of the factors that can diminish vaccine effectiveness in any given season. Cell-based and recombinant flu vaccines, which bypass eggs entirely, are available as alternatives. For older adults or their caregivers who want to maximize their chances of getting the best possible match, asking a pharmacist or physician about non-egg-based options is a reasonable step, though availability can vary.
Could mRNA Technology Make Flu Shots More Consistent?
The mRNA vaccine technology that proved its speed and adaptability during the COVID-19 pandemic is now being applied to influenza, and early results are encouraging. Experimental mRNA flu vaccines have shown higher effectiveness than conventional flu shots in clinical trials, according to reporting from the University of Minnesota’s Center for Infectious Disease Research and Policy. The potential advantage is significant: mRNA vaccines can be updated and manufactured more quickly than egg-based vaccines, which could narrow the window between strain selection and vaccine delivery and reduce the chance of a mismatch.
However, these vaccines are not yet widely available for influenza, and clinical trials have shown they cause more side effects than conventional shots. Southern Hemisphere data from early 2025 showed flu vaccine protection around 50 percent, which helped inform Northern Hemisphere vaccine composition for the current season, but the fundamental prediction problem remains. mRNA technology may eventually improve year-to-year consistency, but it will not eliminate the challenge of a virus that mutates unpredictably. For now, the most practical approach for dementia caregivers and older adults is to use the best available vaccine each season, stay informed about which formulations are recommended for their age group, and combine vaccination with other protective measures like hand hygiene and avoiding crowded indoor spaces during peak flu activity.
Conclusion
Flu vaccine effectiveness varies year to year because of a basic mismatch between the speed of viral mutation and the timeline required to produce vaccines. H3N2 strains are the worst offenders, age and immune status further shape individual protection, and manufacturing methods can introduce additional drift. The 2025–2026 season has underscored all of these challenges, with overall effectiveness running lower than recent seasons, particularly for older adults. Yet even at 33 percent effectiveness, the vaccine has prevented a meaningful share of the 26 million flu illnesses and 340,000 hospitalizations estimated during this period.
For families navigating dementia care, the flu shot remains one of the simplest and most impactful steps available to protect a vulnerable loved one. A severe flu infection in someone with cognitive impairment can trigger hospitalization, delirium, accelerated decline, and death. Imperfect protection is still protection. Get vaccinated, ask about high-dose or cell-based options for anyone over 65, vaccinate all caregivers and household members, and watch for developments in mRNA flu vaccines that may bring more reliable coverage in coming years.
Frequently Asked Questions
Is the flu shot still worth getting if it only works 33 percent of the time?
Yes. Even at lower effectiveness levels, the vaccine reduces the risk of severe illness, hospitalization, and death. For older adults and people with dementia, avoiding a severe flu episode can prevent cascading health complications including cognitive decline that may not be reversible.
Should someone with dementia get the regular flu shot or a special version?
Adults 65 and older, including those with dementia, are generally recommended to receive a high-dose, adjuvanted, or recombinant flu vaccine rather than the standard-dose shot. These formulations are designed to produce a stronger immune response in aging immune systems. Discuss the options with a physician.
Can the flu shot cause or worsen dementia symptoms?
No. The flu vaccine does not cause dementia or accelerate cognitive decline. In fact, some observational research has suggested that regular flu vaccination may be associated with a reduced risk of developing dementia, though more study is needed to confirm a causal relationship.
Why can’t scientists just update the flu vaccine faster to match the current strains?
Egg-based vaccine manufacturing requires months of lead time for virus growth, testing, and distribution. mRNA technology could shorten this timeline significantly, but mRNA flu vaccines are still in clinical trials and not yet widely available for seasonal influenza.
Does the flu vaccine protect against all types of flu?
Current flu vaccines are designed to protect against multiple strains, typically two influenza A subtypes and one or two influenza B lineages. However, effectiveness varies by strain. This season, the vaccine worked better against influenza B (45 to 71 percent among children, 63 percent among adults) than against H3N2 (35 percent among children).
